Glysantis has developed a proprietary nanotechnology platform based on monodisperse nano-glycogen extracted from sweet corn. These naturally assembled nanoparticles are safe, non-toxic, fully biodegradable and can be chemically modified. Glysantis' R&D efforts are developing applications in diverse areas such as vaccine biomanufacturing, adjuvants, anti-infectives, oral health, anti-inflammation and targeted drug delivery. Our scalable technology provides safe nanoparticles for a wide range of applications.